SIGA TECHNOLOGIES INC. - COMMON STOCK

SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results

27 Oct 2022 15:15:00 By Nasdaq GlobeNewswire

SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox

12 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®

29 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)

26 Sep 2022 09:07:14 By Nasdaq GlobeNewswire

SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®

09 Aug 2022 06:30:00 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022

04 Aug 2022 15:05:07 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results

28 Jul 2022 15:15:00 By Nasdaq GlobeNewswire

SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

15 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

12 Jul 2022 15:15:00 By Nasdaq GlobeNewswire

SIGA Technologies Receives Approval from UK for Tecovirimat

08 Jul 2022 06:30:00 By Nasdaq GlobeNewswire

SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

23 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022

22 Jun 2022 09:13:44 By Nasdaq GlobeNewswire

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)

19 May 2022 06:30:00 By Nasdaq GlobeNewswire

New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®

12 May 2022 15:05:01 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Three Months Ended March 31, 2022

05 May 2022 15:05:02 By Nasdaq GlobeNewswire

SIGA Declares Special Dividend of $0.45 Per Share

05 May 2022 06:30:01 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results

28 Apr 2022 15:05:02 By Nasdaq GlobeNewswire

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021

03 Mar 2022 15:05:01 By Nasdaq GlobeNewswire

SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials

02 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results

24 Feb 2022 09:27:12 By Nasdaq GlobeNewswire